For optimal GDMT for patients with HFrEF and co-existing ESRD, is there evidence to support the use of SGLT2 inhibitors and/or ARB/ARNI?

For patients with heart failure with reduced ejection fraction (HFrEF) and co-existing end-stage renal disease (ESRD), the use of sodium-glucose co-transporter-2 inhibitors SGLT2i and angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor ARB/ARNI therapies requires careful consideration.

SGLT2 inhibitors: The DAPA-HF and EMPEROR-Reduced trials excluded patients with an estimated glomerular filtration rate (eGFR) <20-30 mL/min/1.73 m², limiting direct evidence for their use in ESR...

No